Volume 13 Supplement 4

Abstracts of the Tenth International Congress on Drug Therapy in HIV Infection

Meeting abstracts

Glasgow, UK7-11 November 2010

Page 2 of 6

Pooled week 48 safety and efficacy results from the ECHO and THRIVE phase III trials comparing TMC278 vs EFV in treatment-naïve, HIV-1-infected patients

Authors: C Cohen, JM Molina, P Cahn, B Clotet, J Fourie, B Grinsztejn, W Hao, M Johnson, K Supparatpinyo, HM Crauwels, L Rimsky, S Vanveggel, P Williams and K Boven

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):O48

Content type: Oral presentation Published on: 8 November 2010
- View Full Text
- View PDF
Lersivirine: a new NNRTI active across HIV-1 subtypes with a unique resistance profile

Authors: J Mori, M Westby, M Tawadrous, E van der Ryst and C Charles

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):O49

Content type: Oral presentation Published on: 8 November 2010
- View Full Text
- View PDF
Once-daily S/GSK1349572 combination therapy in antiretroviral-naïve adults: rapid and potent 24-week antiviral responses in SPRING-1 (ING112276)

Authors: J Rockstroh, F Felizarta, F Maggiolo, F Pulido, HJ Stellbrink, O Tsybakova, P Yeni, S Almond, C Brothers, I Song and S Min

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):O50

Content type: Oral presentation Published on: 8 November 2010
- View Full Text
- View PDF
Activity of the integrase inhibitor S/GSK1349572 in subjects with HIV exhibiting raltegravir resistance: week 24 results of the VIKING study (ING112961)

Authors: J Eron, JM Livrozet, P Morlat, A Lazzarin, C Katlama, T Hawkins, T Fujiwara, R Cuffe, C Vavro, J Santiago, M Ait-Khaled, S Min and JM Yeo

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):O51

Content type: Oral presentation Published on: 8 November 2010
- View Full Text
- View PDF
Health-related quality of life and fatigue in HIV-1 infected patients diagnosed during primary versus chronic infection

Authors: R Steingrover, MAF Nievaard, JMA Lange, PT Nieuwkerk and JM Prins

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P1

Content type: Poster presentation Published on: 8 November 2010
- View Full Text
- View PDF
The management of acute retroviral syndrome

Authors: A Hristea, R Petre, S Gliga, I Olaru, M Ion, R Moroti, C Popescu, R Mihailescu, M Radulescu and V Arama

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P2

Content type: Poster presentation Published on: 8 November 2010
- View Full Text
- View PDF
ARTEMIS: 192-week efficacy and safety of once-daily darunavir/ritonavir (DRV/r) vs lopinavir/r (LPV/r) in treatment-naïve HIV-1-infected adults

Authors: C Orkin, E DeJesus, H Khanlou, A Stoehr, K Supparatpinyo, T Van de Casteele, E Lathouwers and S Spinosa-Guzman

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P3

Content type: Poster presentation Published on: 8 November 2010
- View Full Text
- View PDF
Nevirapine (NVP) vs ritonavir-boosted atazanavir (ATV/r) combined with tenofovir/emtricitabine (TDF/FTC) in first-line therapy: NEWART 48-week data

Authors: E DeJesus, A Mills, L Bhatti, C Conner and S Storfer

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P4

Content type: Poster presentation Published on: 8 November 2010
- View Full Text
- View PDF
Efficacy and safety of an NRTI-sparing regimen in antiretroviral-naïve HIV-infected patients: once-daily maraviroc plus lopinavir/ritonavir

Authors: S Nozza, L Galli, M Di Pietro, F Mazzotta, F Canducci, M Pogliaghi, S Chiappetta, A Galli, V Rusconi, S Salpietro, G Tambussi and A Lazzarin

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P5

Content type: Poster presentation Published on: 8 November 2010
- View Full Text
- View PDF
5-year safety and efficacy of the once-daily antiretroviral regimen of efavirenz (EFV)/emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)

Authors: A Lazzarin, M Johnson, E Ribera, L Weitner, SS Chen and DR Warren

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P6

Content type: Poster presentation Published on: 8 November 2010
- View Full Text
- View PDF
SUPPORT: 48-week results of fosamprenavir/ritonavir vs efavirenz with abacavir/lamivudine in under-represented, antiretroviral-naïve patients

Authors: P Kumar, E DeJesus, G Huhn, L Sloan, F Garcia, C Small, H Edelstein, F Felizarta, R Hao, B Ha, B Stancil, L Ross, K Oie and K Pappa

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P7

Content type: Poster presentation Published on: 8 November 2010
- View Full Text
- View PDF
HRQoL improves in treatment-naïve HIV-1 subjects initiated on lopinavir/ritonavir (LPV/r) with raltegravir (RAL) or tenofovir/emtricitabine (TDF/FTC)

Authors: RW Baran, B Dietz, LM Fredrick, M Tian and T Podsadecki

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P8

Content type: Poster presentation Published on: 8 November 2010
- View Full Text
- View PDF
Outcomes in antiretroviral-naive HIV-infected patients initiating therapy with TDF/FTC plus either atazanavir/r or another third recommended drug

Authors: E Billaud, JM Lacombe, A Abgrall, J Ghosn, O Launay, JM Livrozet, JL Meynard, J Pavie and D Costagliola

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P9

Content type: Poster presentation Published on: 8 November 2010
- View Full Text
- View PDF
Comparing the effectiveness of efavirenz and nevirapine for first-line antiretroviral treatment amongst an adult treatment cohort from South Africa

Authors: P Bock, G Fatti and A Grimwood

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P10

Content type: Poster presentation Published on: 8 November 2010
- View Full Text
- View PDF
Comparative efficacy and safety of regimens including ritonavir-boosted lopinavir or nevirapine in antiretroviral-naïve HIV-1-infected individuals

Authors: A Pereira, JP Lopes da Cruz, C Carvalho, C Gonçalves and F Antunes

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P11

Content type: Poster presentation Published on: 8 November 2010
- View Full Text
- View PDF
Efficacy and safety of TDF/FTC-containing, first-line HAART in clinical practice: 3-year data from the German outpatient cohort

Authors: J van Lunzen, G Fätkenheuer, T Lutz, S Klauke, S Mauss, H Knechten, P Braun, L Gallo and J Goldbach

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P12

Content type: Poster presentation Published on: 8 November 2010
- View Full Text
- View PDF
Reasons for treatment discontinuation in the first year after beginning antiretroviral therapy in a cohort of Portuguese HIV-infected patients

Authors: C Caldas, P Andrade, C Azevedo, C Piñeiro, R Serrão, J Soares, R Marques and A Sarmento

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P13

Content type: Poster presentation Published on: 8 November 2010
- View Full Text
- View PDF
Insights into antiretroviral treatment changes in previously naïve patients: results of a Portuguese cohort

Authors: C Silva, D Bento, J Rijo, D Alfaiate, I Aldir, C Araújo, H Farinha and K Mansinho

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P14

Content type: Poster presentation Published on: 8 November 2010
- View Full Text
- View PDF
Factors associated with treatment modification during the first year of contemporary HAART

Authors: N Martin, I Perez-Valero, B San Jose Valiente, M Mora, JI Bernardino-Serna, J Gonzalez, F Gaya, FX Zamora, JM Pena and JR Arribas

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P15

Content type: Poster presentation Published on: 8 November 2010
- View Full Text
- View PDF
Impact of timing HAART initiation on immune status and clinical course in the cohort of the German competence network for HIV/AIDS

Authors: A Plettenberg, NH Brockmeyer, B Haastert, S Dupke, CK Schewe, M Rausch, M Hower, G Arendt, K Jansen and HIV KompNet

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P16

Content type: Poster presentation Published on: 8 November 2010
- View Full Text
- View PDF
Efficient immune reconstitution in HIV+ naïve patients (pts) starting a first lopinavir/ritonavir-containing regimen with low CD4 counts

Authors: E Merlini, E Sinigaglia, G Carpani, T Bini, A d'Arminio Monforte and GC Marchetti

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P17

Content type: Poster presentation Published on: 8 November 2010
- View Full Text
- View PDF
Immunological response among patients with undetectable viral load followed for 5 years

Authors: C Piñeiro, AS Santos, S Cardoso, J Nuak, R Lucas, A Ferreira, S Xerinda, M Tavares, R Marques and A Sarmento

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P18

Content type: Poster presentation Published on: 8 November 2010
- View Full Text
- View PDF
Epidemiological features, therapeutic strategies and long-term immunological outcomes in virologically suppressed HIV+ very late presenters

Authors: L Martinelli, D Francisci, A Sgrelli and F Baldelli

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P19

Content type: Poster presentation Published on: 8 November 2010
- View Full Text
- View PDF
Sex matters: retrospective data collection on the date of commencement of ART for HIV-positive women and men in the German KompNet cohort (1991-2009)

Authors: I Krznaric, A Wienbreyer, A Zoufaly, P Kreckel, S Esser, T Harrer, K Jansen, C Michalik and S Hertling

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P20

Content type: Poster presentation Published on: 8 November 2010
- View Full Text
- View PDF
Response to HAART according to sex and origin (immigrant vs autochthonous) in a cohort of patients who initiate antiretroviral treatment

Authors: JA Perez-Molina, M Mora-Rillo, I Suarez-Lozano, JL Casado, R Teira, P Rivas, E Pedrol, A Hernando, P Domingo, E Barquilla, H Esteban and J Gonzalez-Garcia

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P21

Content type: Poster presentation Published on: 8 November 2010
- View Full Text
- View PDF
Eligibility for the initiation of HIV treatment in the context of the updated EACS guidelines: results of a clinical audit

Authors: MC Aichelburg, M Schlag and A Rieger

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P22

Content type: Poster presentation Published on: 8 November 2010
- View Full Text
- View PDF
Cross-sectional study of HIV living people cohort to specify indications to antiretroviral treatment in naïve patients

Authors: AJ Pronin and GD Kaminskiy

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P23

Content type: Poster presentation Published on: 8 November 2010
- View Full Text
- View PDF
Changing antiretrovirals whilst viral load <50 copies/ml and relationship with CD4 count changes

Authors: A Mocroft

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P24

Content type: Poster presentation Published on: 8 November 2010
- View Full Text
- View PDF
Influence of demographic and disease parameters on virological response to once- vs twice-daily darunavir/ritonavir (DRV/r) at week 48 in ODIN

Authors: M Sension, C Arns Da Cunha, P Domingo, K Supparatpinyo, T Van De Casteele, P De Doncker and F Tomaka

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P25

Content type: Poster presentation Published on: 8 November 2010
- View Full Text
- View PDF
Health-related quality of life (HRQoL) assessment with once- and twice-daily darunavir/ritonavir (DRV/r) in the ODIN trial

Authors: S Spinosa-Guzman, T Van de Casteele, G De La Rosa and P De Doncker

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P26

Content type: Poster presentation Published on: 8 November 2010
- View Full Text
- View PDF
Darunavir in experienced patients

Authors: G Sterrantino, B Borchi, M Trotta, D Bartolozzi and F Leoncini

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P27

Content type: Poster presentation Published on: 8 November 2010
- View Full Text
- View PDF
Efficacy and tolerability of darunavir/r 600/100 mg bid in treatment-experienced patients: 48-week data from a German outpatient cohort

Authors: J van Lunzen, D Gorriahn, T Wünsche, S Dupke, P Gute, CK Schewe and B Ranneberg

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P28

Content type: Poster presentation Published on: 8 November 2010
- View Full Text
- View PDF
Week 48 efficacy of 900/100 mg daily of darunavir/ritonavir in treatment-experienced HIV-1 patients with virological success: DARDAR study

Authors: L Schneider, A Houssaini, S Lambert, G Peytavin, R Agher, A Chermak, P Flandre, V Calvez, AG Marcelin, J Ghosn and C Katlama

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P29

Content type: Poster presentation Published on: 8 November 2010
- View Full Text
- View PDF
Efficacy and safety of lopinavir/ritonavir (LPV/r) in antiretroviral-experienced subjects infected with different subtypes of HIV-1

Authors: L Maroldo, LM Fredrick, K Robinson-Morgan, R Trinh and TJ Podsadecki

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P30

Content type: Poster presentation Published on: 8 November 2010
- View Full Text
- View PDF
Long-term efficacy and safety of atazanavir/ritonavir treatment in a real-life cohort of treatment-experienced HIV patients

Authors: K Jansen, A Sönnerborg, P Pugliese, S Biguenet, JL Eychenne, NH Brockmeyer, C Michalik, S Dupke, H Jaeger, A Plettenberg, D Butcher, MJ Jiménez-Expósito and HIV KompNet

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P31

Content type: Poster presentation Published on: 8 November 2010
- View Full Text
- View PDF
Integrase inhibitor-based treatment in clinical practice

Authors: G Cenderello, R Piscopo, M Feasi, G Penco, N Bobbio and G Cassola

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P32

Content type: Poster presentation Published on: 8 November 2010
- View Full Text
- View PDF
Switching to a 'nuke-sparing' raltegravir/atazanavir combination: an individualised approach

Authors: A Grant, Y Kamuntu, P Read and R Kulasegaram

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P33

Content type: Poster presentation Published on: 8 November 2010
- View Full Text
- View PDF
Portuguese cohort: raltegravir with optimized background therapy (OBT) in multiple-experienced HIV1- and HIV2-infected patients

Authors: M Doroana, C Piñeiro, F Maltez, P Fonseca, J Oliveira, K Mansinho, A Horta, E Teófilo, M Aguas, I Germano and D Faria

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P34

Content type: Poster presentation Published on: 8 November 2010
- View Full Text
- View PDF
Reasons for using and efficacy of raltegravir in salvage regimens without protease inhibitors in clinical practice

Authors: JM Llibre, E Martínez, P Barreiro, R Escrig, E Ribera, M Cervantes, A Imaz, F Gutierrez, H Knobel, A Ornelas, FX Zamora and B Clotet

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P35

Content type: Poster presentation Published on: 8 November 2010
- View Full Text
- View PDF
Use of once-daily raltegravir-based HAART in HIV-infected injection drug users

Authors: HK Tossonian, JD Raffa, O Alenezi, K Anderson, S Jassemi, K Wight, S DeVlaming and B Conway

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P36

Content type: Poster presentation Published on: 8 November 2010
- View Full Text
- View PDF
Temporal trend of the first prescription of nevirapine: the ANRS CO3 Aquitaine Cohort, 1997-2008

Authors: M Bruyand, S Geffard, S Lawson-Ayayi, F Dauchy, G Miremont-Salamé, C Greib, S Farbos, P Morlat and F Dabis

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P37

Content type: Poster presentation Published on: 8 November 2010
- View Full Text
- View PDF
Long-term follow-up of HIV-infected patients in salvage therapy with raltegravir plus optimized background regimens: a multicentre Italian experience

Authors: S Landonio, P Meraviglia, AF Capetti, A Di Biagio, S Lo Caputo, G Sterrantino, A Ammassari, B Menzaghi, M Franzetti, G De Socio, G Pellicanò, E Mazzotta, P Zucchi and G Rizzardini

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P38

Content type: Poster presentation Published on: 8 November 2010
- View Full Text
- View PDF
Immunologic impact of maraviroc in clinical practice of a university hospital

Authors: S Plata Paniagua, N Trovato Lopez, I Castillo Romera, A Ais Larisgoitia, J Bellon Cano and M Sanjurjo Saez

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P39

Content type: Poster presentation Published on: 8 November 2010
- View Full Text
- View PDF
Short-course intensification with enfuvirtide in virologic failure: impact on intracellular HIV reservoir and on viral tropism (INNOVE study)

Authors: J Ghosn, C Delaugerre, A Pinta, N Pierre, D Etienne, F Raffi and L Morand-Joubert

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P40

Content type: Poster presentation Published on: 8 November 2010
- View Full Text
- View PDF
Efficacy of once daily darunavir/ritonavir 800/100 mg in PI/r-experienced HIV-1 infected patients with suppressed HIV-1 replication: the RADAR study

Authors: J Ghosn, A Chermak, A Houssaini, G Peytavin, S Lambert-Niclot, N Eychenne, L Slama, A Brunet, C Duvivier, A Simon, AG Marcelin, P Flandre and C Katlama

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P41

Content type: Poster presentation Published on: 8 November 2010
- View Full Text
- View PDF
Switching to Atripla (EFV/FTC/TDF) from Kivexa (ABC/3TC) plus EFV leads to improved perceptions of treatment: results from the ROCKET 1 study

Authors: V Cooper, R Horne and J Ewan

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P42

Content type: Poster presentation Published on: 8 November 2010
- View Full Text
- View PDF
Long-term outcomes of switching to fixed-dose abacavir/lamivudine (ABC/3TC) or tenofovir/emtricitabine (TDF/FTC): 3-year results of the BICOMBO study

Authors: E Martínez, JA Arranz, D Podzamczer, M Lonca, J Sanz, P Barragán, H Knobel, E Ribera, F Gutierrez, S Valero, B Clotet, D Dalmau, F Segura, JR Arribas, P Barrufet, I Santos…

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P43

Content type: Poster presentation Published on: 8 November 2010
- View Full Text
- View PDF
Tolerance and durability of abacavir/lamivudine (ABC/3TC)-containing regimens: results from a large prospective French cohort

Authors: L Cuzin, C Allavena, L Levy-Bachelot, MA Valantin, H Mellliez, P Pugliese, I Poizot-Martin, C Duvivier, L Finkielsztejn and S Abel

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P44

Content type: Poster presentation Published on: 8 November 2010
- View Full Text
- View PDF
48-week efficacy and safety of transitioning virologically stable HIV-1 patients from nevirapine IR 200 mg BID to nevirapine XR 400 mg QD (TRANxITION)

Authors: K Arastéh, A Ward, A Plettenberg, JM Livrozet, C Cordes, A Winston, E Wang and A Quinson

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P45

Content type: Poster presentation Published on: 8 November 2010
- View Full Text
- View PDF
Lopinavir to atazanavir or darunavir switch in HIV-1-infected patients with dyslipidemia: an observational study

Authors: G Le Moal, G Beraud, T Prazuck, L Hocqueloux, A Dupuis and N Venisse

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P46

Content type: Poster presentation Published on: 8 November 2010
- View Full Text
- View PDF

Abstracts of the Tenth International Congress on Drug Therapy in HIV Infection

Meeting abstracts

Journal of the International AIDS Society